We Can Medicines Valuation
Is 6929 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6929 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 6929 (NT$72.5) is trading above our estimate of fair value (NT$6.84)
Significantly Below Fair Value: 6929 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6929?
Other financial metrics that can be useful for relative valuation.
What is 6929's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | NT$3.21b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.4x |
Enterprise Value/EBITDA | 51.4x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 6929's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1.1x | ||
4175 MedFirst Healthcare Services | 0.4x | n/a | NT$3.2b |
6844 Norbel Baby | 1.7x | n/a | NT$6.2b |
6469 Great Tree Pharmacy | 2x | 17.0% | NT$32.6b |
2945 Simple Mart Retail | 0.2x | n/a | NT$3.1b |
6929 We Can Medicines | 1x | n/a | NT$3.2b |
Price-To-Sales vs Peers: 6929 is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (1.1x).
Price to Earnings Ratio vs Industry
How does 6929's PE Ratio compare vs other companies in the Asian Consumer Retailing Industry?
Price-To-Sales vs Industry: 6929 is expensive based on its Price-To-Sales Ratio (1x) compared to the Asian Consumer Retailing industry average (0.5x).
Price to Sales Ratio vs Fair Ratio
What is 6929's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 1x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6929's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.